Introduction

Moyamoya Disease (MMD) is an uncommon disorder that causes blood vessels in the brain to constrict over time. This constriction heightens the risk of strokes and other neurological problems. Understanding how blood flows in the brain is critical for proper diagnosis and therapy, which is where cerebrovascular reactivity testing comes in.

This test assesses how effectively the brain's blood arteries adapt to variations in blood flow, providing valuable information regarding the risk of ischemia and general brain health. By analysing these reactions, surgeons may pinpoint areas of the brain that may be at risk, allowing them to schedule procedures and make treatment decisions that result in improved results for patients.

This article discusses the significance of cerebrovascular reactivity testing in identifying and managing Moyamoya disease, emphasising its enhancement to patient care and informs treatment methods.

What is Moyamoya Disease?

MMD is an uncommon, chronic disorder that impairs blood flow in the brain, and was initially discovered by Japanese surgeons in 1957. This condition is characterised by the constriction or blocking of the terminal parts of both internal carotid arteries, which feed blood to the brain. This results in the creation of a unique network of blood arteries surrounding the occluded sites.

The condition can induce ischemic episodes (temporary decreases in blood flow) or cerebral infarctions (strokes), which are more prevalent in children than in adults. In adults, it can cause a cerebral hemorrhage. Moyamoya can affect individuals of any age, however it is most commonly diagnosed in children under the age of ten.

The afflicted arteries exhibit thickening of the inner layer, increased smooth muscle cells, and a twisted internal structure. Notably, there is often no plaque accumulation in the arteries.

Genetics

The etiology of Moyamoya illness is not entirely known. However, it appears to have a genetic component, since it is more frequent among persons of Japanese and Korean descent, with around 10% having a family history. Recent genetic study has identified specific regions on chromosomes 3, 6, and 17 that may be related to the condition.

History

Doctors Takeuchi and Shimizu originally described Moyamoya illness in 1957, observing that both internal carotid arteries were undeveloped. Over time, it became evident that the thick network of blood vessels seen in this condition is a result of the narrowing or blockage of arteries.

This syndrome is often considered acquired, which means it is not present at birth. It is officially known in Japan as "spontaneous occlusion of the circle of Willis." However, in 1967, researchers Suzuki and Takaku gave it the moniker "Moyamoya," which translates to a smoky or hazy appearance, describing how aberrant blood vessels appear on imaging examinations.

Suzuki and Takaku discovered six phases of the illness:

• Narrowing of the carotid siphon
• Initiation of collateral vessel formation
• Intensification of the disease
• Minimization of symptoms
• Reduction of blood vessels
• Disappearance of Moyamoya vessels

Since its discovery, extensive research has been conducted, particularly in Japan, but cases have been reported in many other countries as well. Since 1977, a national research committee has been organized in Japan to study this disease further.

Clinical Features

• The internal carotid arteries, as well as the proximal middle and anterior cerebral arteries, narrow over time
• Angiographic look: A characteristic "puff of smoke" look caused by the development of collateral blood vessels during imaging
• Bilateral involvement usually affects both sides of the brain; unilateral involvement is known as Moyamoya syndrome (MMS)

Signs and Symptoms

• Ischemic Events:
  • Most common initial symptom, especially in children
  • Can lead to strokes or transient ischemic attacks (TIAs)
• Hemorrhagic Events:
  • Rare in children; increased incidence in teenagers
  • Can result in significant intracerebral hemorrhage
• Silent Microbleeds:
  • High incidence of small, unnoticed bleeds detected by advanced MRI
• Cognitive and Developmental Delays:
  • Increased incidence of delays in language, cognitive skills, and executive function in children
• Headaches:
  • Commonly reported, resembling migraines
  • Caused by irritation from dilating blood vessels
• Triggers for Ischemia:
  • Hyperventilation (e.g., during emotional outbursts) can provoke ischemic events
• Increased Risk Factors:
  • Low oxygen levels (hypoxia)
  • Low blood pressure (hypotension)
  • Low carbon dioxide levels (hypocapnia)
  • High body temperature (hyperthermia)
• Seizures:
  • Higher risk due to cortical irritation, which may lead to ischemic events
• Age of Diagnosis:
  • Peaks around age five in children; often diagnosed in the 30s for adults
• Gender Ratio:
  • Affects women nearly twice as often as men in adults (2:1 ratio)
• Associated Conditions:
  • Higher incidence in individuals with:
    • Neurofibromatosis type I
    • Sickle cell disease
    • Down's syndrome
• Moyamoya Syndrome (MMS):
  • More common in adults, often related to secondary causes like radiation therapy
• Progressive Nature:
  • Symptoms may worsen over time, with potential for new blood vessel growth as the disease advances

Diagnosis

The best way to diagnose MMD is via a particular imaging technique known as catheter-based digital subtraction angiography (DCA). Researchers Suzuki and Takaku arranged this procedure into a six-stage framework to assist clinicians to follow the disease's progression.

MMD phases frequently reflects the evolution of the disease. Children often go through these stages more quickly, but adults frequently remain constant in one stage.

Imaging Techniques

• MRI Imaging: MRI scans are useful for identifying parts of the brain that have had a shortage of blood supply or have suffered from strokes. A particular pattern detected on MRI, known as the "ivy sign," can suggest MMD. Furthermore, MRI can reveal "termite nest" symptoms, which are another indicator of the condition.

DCA is important because it allows clinicians to identify the appropriate blood artery for surgical treatments such as bypass surgery. Sometimes, a smaller blood channel is not appropriate, and a larger one is preferable.

Additional Imaging Techniques:

• Perfusion Imaging: Techniques such as perfusion-weighted imaging (PWI) and CT perfusion are useful for both before and after surgery. Before surgery, these scans reveal parts of the brain that may still be healthy but might benefit from increased blood flow
• Monitoring Surgery Success: Following surgery, doctors utilise imaging to monitor blood flow and whether it has improved, indicating the success of the surgery. Blood flow can be monitored using a technique known as Transcranial Doppler (TCD)
• Intraoperative technologies: During surgery, surgeons utilise technologies such as ultrasonography to find blood arteries and guarantee proper blood flow via grafts. They also utilise a unique luminous dye to ensure that the grafts are functioning correctly

Overall, these imaging modalities are critical for accurately detecting and controlling MMD, contributing to better patient outcomes.

What is Cerebrovascular Reactivity Testing?

Cerebrovascular reactivity (CVR) testing is a specialised physiological assessment used to evaluate how effectively cerebral blood vessels respond to changes in vasoactive stimuli, primarily alterations in carbon dioxide (CO₂) levels. This testing provides crucial insights into the regulation and health of cerebral blood flow (CBF), which is essential for maintaining optimal oxygen and nutrient delivery to the brain tissue.

How is CVR Measured?

CVR is typically measured through various controlled stimuli that influence cerebral blood vessel diameter, thereby affecting CBF. The most common methods include:

1. Carbon dioxide (CO₂) inhalation: Subjects breathe a gas mixture with altered CO₂ concentrations compared to normal atmospheric levels. CO₂ acts as a potent vasodilator, causing cerebral blood vessels to dilate when levels are elevated and constrict when levels decrease. This dynamic response allows for the assessment of how effectively the brain's blood vessels regulate blood flow in response to changes in CO₂
2. Breath-holding: Breath-holding induces a temporary increase in CO₂ levels in the blood due to reduced ventilation. This method can be used to observe the subsequent changes in CBF as the brain responds to the elevated CO₂ levels
3. Pharmacological agents: Certain medications, such as acetazolamide, can be administered to induce a controlled increase in blood CO₂ levels. Acetazolamide inhibits carbonic anhydrase, an enzyme that catalyses the breakdown of CO₂, leading to an accumulation of CO₂ and subsequent vasodilation of cerebral blood vessels
4. Other vasoactive stimuli: In addition to CO₂, other stimuli like oxygen inhalation or specific cognitive tasks can be used to assess CVR. These stimuli provoke changes in neural activity or metabolic demand, influencing CBF and providing insights into cerebrovascular function

Steps for Conducting CVR Testing:

1. Subject preparation:
   • Obtain informed consent from the subject and explain the procedure in detail
   • Ensure the subject is comfortable, relaxed, and understands the tasks involved
   • Minimise external factors that could influence breathing patterns or attention during the test
2. Baseline Measurement:
   • Establish baseline measurements of CBF or related parameters using appropriate imaging or monitoring techniques (e.g., TCD ultrasound, arterial spin labeling MRI)
3. Administration of Vasoactive Stimulus:
   • Administer the chosen vasoactive stimulus (CO₂ inhalation, breath-holding, pharmacological agent) in a controlled and systematic manner
   • Monitor the subject closely throughout the stimulus administration to ensure safety and compliance with the protocol
4. Measurement of Cerebrovascular Response:
   • Continuously or periodically measure changes in CBF or related parameters during and after the stimulus
   • UtiliSe imaging or monitoring techniques to quantify and record the responses of cerebral blood vessels to the vasoactive stimuli
5. Data Analysis and Interpretation:
   • Analyse the collected data to assess the magnitude and pattern of the cerebrovascular response
   • Compare responses to baseline measurements and between different stimuli if multiple tests are conducted
   • Interpret the findings within the context of normal ranges or expected responses for the subject’s age, health status, and relevant clinical or research objectives
6. Documentation and Reporting:
   • Document all procedures, measurements, and observations meticulously
   • Prepare a comprehensive report summarising the experimental protocol, quantitative results, and qualitative observations
   • Discuss the clinical implications or research findings derived from CVR testing, including any implications for cerebrovascular health or function

Considerations and Challenges

• Technical setup and calibration: Ensure proper functioning and calibration of equipment used for stimulus delivery, monitoring CBF, and recording data to maintain accuracy and reliability
• Subject comfort and compliance: Create a conducive testing environment to minimise artifacts from subject discomfort or involuntary movements that could affect data quality
• Data variability: Recognise and address potential sources of variability, such as vrespiratory rate or subject positioning, to enhance the consistency and reliability of CVR measurements
• Safety monitoring: Maintain vigilant monitoring of subjects during CVR testing, particularly during interventions like CO₂ inhalation, to mitigate potential risks and ensure participant safety

In summary, CVR testing is a valuable tool for evaluating cerebrovascular function and responsiveness in both clinical and research settings. By assessing how cerebral blood vessels react to vasoactive stimuli, clinicians and researchers can gain insights into brain perfusion regulation, vascular health, and potential implications for neurological conditions or disease states affecting cerebral blood flow dynamics.

Living with Moyamoya Disease

Significance of CVR Testing in Moyamoya Disease

CVR testing, particularly using techniques like resting state (RS) blood oxygenation level dependent (BOLD) functional MRI, is crucial in MMD for assessing the brain's ability to adapt to changes in blood flow demands. This testing helps evaluate the effectiveness of treatments such as revascularisation surgery in improving CVR in affected brain regions. MMD typically leads to reduced CVR, making such assessments critical for treatment planning and monitoring.

Treatment and Management of Moyamoya Disease

• Revascularisation surgery: This surgical intervention aims to improve blood flow to the brain by creating new routes for blood circulation, reducing the risk of ischemic events. RS CVR mapping has shown that surgery can significantly improve CVR in the middle cerebral artery (MCA) territory, which is typically affected in MMD
• Medical management: While surgical intervention is the primary treatment, medical management focuses on preventing complications such as stroke through medications and lifestyle modifications

Lifestyle Management

Lifestyle modifications play a supportive role in managing MMD:

• Medication adherence: Compliance with prescribed medications to manage risk factors like hypertension and hyperlipidemia is crucial
• Healthy diet: Adopting a diet low in saturated fats and cholesterol to promote cardiovascular health
• Physical activity: Encouraging regular exercise within recommended limits to maintain overall health
• Smoking cessation: Quitting smoking to reduce the risk of vascular complications

Prognosis

• Improved diagnosis and monitoring: RS CVR mapping offers a non-invasive method for ongoing monitoring of CVR in individuals with MMD, aiding in early detection of disease progression or treatment efficacy
• Enhanced surgical outcome assessment: It facilitates the assessment of surgical outcomes by measuring changes in CVR post-surgery, correlating with improved prognosis and reduced risk of ischemic events

Future Outlook: Hope for Advancement

• Advancements in imaging techniques: Continued advancements in RS BOLD functional MRI and other imaging modalities hold promise for enhancing the specificity and accuracy of CVR mapping in MMD
• Personalised treatment approaches: Future research aims to tailor treatment strategies based on individual CVR profiles, optimising surgical outcomes and long-term prognosis
• Exploring novel therapies: Research into novel therapies, including potential neuroprotective agents and genetic studies, offers hope for improving outcomes and quality of life for individuals with MMD

Conclusion

MMD poses significant challenges due to its progressive nature and potential for severe neurological complications. CVR testing emerges as a critical tool in understanding and managing this condition. By assessing how cerebral blood vessels respond to stimuli, CVR testing helps clinicians tailor treatments, monitor disease progression, and predict outcomes following interventions like revascularisation surgery. Advances in imaging techniques and personalised treatment approaches offer hope for further improving outcomes and quality of life for individuals with MMD in the future.

Frequently Asked Questions (FAQs)

How does MMD affect cognitive function and development?

MMD can lead to cognitive and developmental delays, especially in children. These delays may include difficulties in language acquisition, executive function, and overall cognitive skills. Early detection and management are crucial to mitigate these effects.

What are the risk factors associated with MMD?

While the exact cause of MMD is not fully understood, certain factors increase the risk. These include genetic predisposition, with higher prevalence among individuals of Japanese and Korean descent, and potential associations with conditions like neurofibromatosis type I and sickle cell disease.

What imaging techniques are used to monitor MMD progression?

Besides digital subtraction angiography (DCA) and MRI, what other imaging modalities are used to monitor Moyamoya disease progression? Are there any specific advantages of each technique?

What are the challenges in managing MMD in adults versus children?

MMD presents unique challenges in management across different age groups. How do treatment approaches differ for children versus adults, considering factors like disease progression rates and surgical outcomes?

What are the latest advancements in research for Moyamoya disease?

Are there any promising treatments or research areas currently being explored for Moyamoya disease? How might these advancements impact future treatment strategies and patient outcomes?